PL2868315T3 - Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty - Google Patents

Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty

Info

Publication number
PL2868315T3
PL2868315T3 PL14188334T PL14188334T PL2868315T3 PL 2868315 T3 PL2868315 T3 PL 2868315T3 PL 14188334 T PL14188334 T PL 14188334T PL 14188334 T PL14188334 T PL 14188334T PL 2868315 T3 PL2868315 T3 PL 2868315T3
Authority
PL
Poland
Prior art keywords
lyophilates
lyophilization
methods
improved formulations
formulations
Prior art date
Application number
PL14188334T
Other languages
English (en)
Inventor
Martin Sven Jacobson
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of PL2868315T3 publication Critical patent/PL2868315T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14188334T 2007-12-04 2008-12-03 Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty PL2868315T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99224107P 2007-12-04 2007-12-04
EP14188334.8A EP2868315B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby
EP08857974.3A EP2224913B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby

Publications (1)

Publication Number Publication Date
PL2868315T3 true PL2868315T3 (pl) 2018-06-29

Family

ID=40718143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14188334T PL2868315T3 (pl) 2007-12-04 2008-12-03 Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty

Country Status (14)

Country Link
US (6) US8277845B2 (pl)
EP (2) EP2224913B1 (pl)
JP (5) JP5812318B2 (pl)
CN (1) CN101932308B (pl)
CA (2) CA3123813A1 (pl)
CY (1) CY1119256T1 (pl)
DK (1) DK2868315T3 (pl)
ES (1) ES2638977T3 (pl)
HR (1) HRP20171223T1 (pl)
LT (1) LT2868315T (pl)
PL (1) PL2868315T3 (pl)
PT (1) PT2868315T (pl)
SI (1) SI2868315T1 (pl)
WO (1) WO2009073711A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224913B1 (en) * 2007-12-04 2014-10-15 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
WO2013086292A1 (en) * 2011-12-09 2013-06-13 Enject, Inc. Glucagon formulations
EP2846787B1 (en) 2012-05-08 2018-08-29 Aeromics, Inc. Compounds for use in the treatment of aquaporin-mediated diseases
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US9949991B2 (en) 2013-11-06 2018-04-24 Aeromics, Inc. Methods of treating aquaporin-mediated conditions
CN106456315B (zh) * 2014-03-07 2021-06-25 恩朵罗杰克斯有限责任公司 形成水凝胶和用于形成水凝胶的材料
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
ES2927482T3 (es) 2015-05-29 2022-11-07 Univ Maryland Métodos para reducir o prevenir el daño de la íntima causado por la estimulación mecánica de las células endoteliales
KR20180063296A (ko) 2015-10-07 2018-06-11 바이오젠 체사피크 엘엘씨 Cns 부종과 관련한 손상 또는 병태의 치료 방법
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
EP4299127A3 (en) 2016-07-29 2024-05-15 Remedy Pharmaceuticals, Inc. Methods of medical treatment with sur1-trpm4 channel inhibitors
CN108210501B (zh) * 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法
CN110753667B (zh) 2017-06-30 2021-08-31 村田机械株式会社 搬运系统以及搬运方法
CN108553428A (zh) * 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法
WO2022195112A1 (en) 2021-03-19 2022-09-22 Eligo Bioscience Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins for treating acneiform rash
CN113274361B (zh) * 2021-06-08 2022-05-06 吉林津升制药有限公司 一种烟酰胺冻干粉针剂及其制备方法
WO2023168379A1 (en) * 2022-03-03 2023-09-07 Biogen Chesapeake Llc Low-sorbing glyburide kit, formulation and methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
GB9003185D0 (en) * 1990-02-13 1990-04-11 Ici Plc Pharmaceutical compositions
JPH07503154A (ja) 1992-01-21 1995-04-06 エス・アール・アイ・インターナシヨナル 微細化ポリペプチド薬剤の改良調製方法
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
CN1046516C (zh) * 1994-04-25 1999-11-17 协和发酵工业株式会社 化合物dx-52-1的稳定方法和其冻干组合物
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
CA2275890C (en) * 1996-12-24 2011-11-01 Biogen, Inc. Stable liquid interferon formulations
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ES2219895T3 (es) 1997-07-29 2004-12-01 PHARMACIA &amp; UPJOHN COMPANY Formulacion autoemulsionante para compuestos lipofilos.
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
BR9815966A (pt) * 1998-05-29 2001-02-28 Biogen Inc Formulação humano de interferon beta-1a (ifn-beta-1a) recombinante
US6552082B2 (en) 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
JP3956654B2 (ja) 2000-06-29 2007-08-08 小野薬品工業株式会社 N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物含有溶液および製剤
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
AU2002306461A1 (en) 2001-03-28 2002-10-15 Rheologics, Inc. In vivo delivery methods and compositions
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US20030125338A1 (en) * 2001-06-12 2003-07-03 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
ES2300460T3 (es) * 2001-07-17 2008-06-16 N-Gene Research Laboratories Inc. Combinaciones farmaceuticas sinergicas destinadas a la prevencion o al tratamiento de la diabetes.
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
DK1529058T3 (da) 2002-03-20 2013-12-02 Us Of America As Represented By The Dept Of Veterans Affairs Ikke-selektiv kationkanal i nerveceller og sur1-antagonister til behandling af hjernehævelse
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
GB0316237D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
DE10341414A1 (de) 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
WO2005112949A1 (en) * 2004-05-20 2005-12-01 Diamedica Inc. Use of drug combinations for treating insulin resistance
ATE487484T1 (de) * 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
US20060183803A1 (en) * 2005-02-17 2006-08-17 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of assorted health problems
US7659281B2 (en) * 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
BRPI0715279A2 (pt) 2006-09-29 2013-06-11 Infa Sa sistema de embalagem, sistema de embalagem para uma composiÇço farmacÊutica, mÉtodo para transferir uma composiÇço farmcÊutica para administraÇço por infusço intravenosa, uso de um sistema de embalagem, kit para administraÇço parenteral de fÁrmacos com um acesso intravenoso e kit admnistraÇço parenteral de princÍpios ativos
EP2224913B1 (en) * 2007-12-04 2014-10-15 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby

Also Published As

Publication number Publication date
CN101932308B (zh) 2014-11-05
HRP20171223T1 (hr) 2017-11-03
US8858997B2 (en) 2014-10-14
JP6866438B2 (ja) 2021-04-28
JP2020007334A (ja) 2020-01-16
JP2018197244A (ja) 2018-12-13
JP5812318B2 (ja) 2015-11-11
JP6603762B2 (ja) 2019-11-06
CN101932308A (zh) 2010-12-29
US20190099372A1 (en) 2019-04-04
CA3123813A1 (en) 2009-06-11
US20200093747A1 (en) 2020-03-26
JP2011505424A (ja) 2011-02-24
EP2224913A4 (en) 2013-04-24
WO2009073711A1 (en) 2009-06-11
US10869835B2 (en) 2020-12-22
JP6377189B2 (ja) 2018-08-22
EP2224913A1 (en) 2010-09-08
JP2017128569A (ja) 2017-07-27
PT2868315T (pt) 2017-09-04
US20150141516A1 (en) 2015-05-21
US8277845B2 (en) 2012-10-02
US20210244669A1 (en) 2021-08-12
US10426729B2 (en) 2019-10-01
JP2015134763A (ja) 2015-07-27
US20100273886A1 (en) 2010-10-28
US20130245069A1 (en) 2013-09-19
SI2868315T1 (sl) 2017-10-30
DK2868315T3 (en) 2017-09-04
CA2707484A1 (en) 2009-06-11
EP2224913B1 (en) 2014-10-15
ES2638977T3 (es) 2017-10-24
EP2868315A1 (en) 2015-05-06
US10117834B2 (en) 2018-11-06
EP2868315B1 (en) 2017-05-31
CA2707484C (en) 2021-08-10
CY1119256T1 (el) 2018-02-14
JP6084639B2 (ja) 2017-02-22
LT2868315T (lt) 2017-09-25

Similar Documents

Publication Publication Date Title
HRP20171223T1 (hr) Poboljšane formulacije i postupci liofiliziranja i tako dobiveni liofilizati
HK1218427A1 (zh) 改進的疫苗及其使用方法
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
ZA201203709B (en) Immunogenic compositions and methods
HK1138188A1 (en) Solid preparation comprising alogliptin and pioglitazone
IL194653A0 (en) Lyophilized therapeutic peptibody formulations
IL197781A0 (en) Lyophilization methods and apparatuses
PT2205336T (pt) Sistema e método para produzir formulações secas
HK1244426A1 (zh) 治療性蛋白質製劑
EP2367444A4 (en) MEDICAL AND NUTRITIONAL FORMULATIONS
EP2209750A4 (en) CEMENT FORMULATIONS AND PRODUCTS
EP2160183A4 (en) QUETIPIN EXTENDED FORMULATIONS WITH EXTENDED RELEASE AND METHOD OF MANUFACTURING THEREOF
EP2185112A4 (en) STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS
GB0719202D0 (en) Compositions and methods for the skin and hair
EP2207567A4 (en) IMMUNOGENIC FORMULATIONS
EP2320739A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR STABILIZATION
ZA200903049B (en) Polymer-linked-bisphosphonate inhalant formulations and methods for using the same
ZA201003524B (en) Injectable meclizine formulations and methods
ZA201008384B (en) Lasalocid compositions and methods
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
GB0725007D0 (en) Carcino-immune therapeutic animal gland extract
GB0713093D0 (en) Pharmaceutical formulations
GB0715066D0 (en) Tobacco extraction methods and formulations